特发性多中心Castleman病-TAFRO或可治愈
该多中心回顾性研究分析27例停药的特发性多中心Castleman病-TAFRO患者,停药时均达生化完全缓解,中位随访31个月后85.2%维持缓解,仅4例进展且再治疗均有效,提示部分患者可尝试停药。
要点
- 停药时达生化完全缓解的iMCD-TAFRO患者可考虑尝试停药。
- 停药后中位随访31个月,85.2%患者维持生化完全缓解。
- 进展患者 pretreatment CRP 显著更低,再治疗均有效。
核心结论
- 部分iMCD-TAFRO患者停药后可维持长期缓解,对达生化完全缓解者可考虑尝试停药。
研究设计与样本
- 多中心回顾性研究,分析27例停药的特发性多中心Castleman病-TAFRO患者。
主要发现
- 停药后中位随访31个月,仅4例(14.8%)疾病进展,其余85.2%维持生化完全缓解。
- 进展患者停药前CRP水平显著低于维持缓解者(43.7 ± 39.3 vs. 126.4 ± 62.5 mg/L,p = 0.018)。
- 停药至进展的中位时间为9.5个月(范围5-12),进展者再治疗均再次缓解。
- 停药后6个月、1年、3年估计PFS分别为96.3%、85.2%、85.2%,全部患者存活。
关键数值与推荐
- 所有患者停药时均达生化完全缓解。
- 59.3%患者接受类骨髓瘤方案治疗,仅11.1%接受抗IL-6治疗。
- 不同治疗方式或治疗时长对长期缓解无显著影响。
临床怎么用
- 对达生化完全缓解的iMCD-TAFRO患者,可与患者沟通后尝试停药并密切随访。
局限性
- 回顾性研究,样本量小(27例),长期数据仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic multicentric Castleman disease (iMCD)-TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis/renal dysfunction, Organomegaly) is the most severe clinical subtype of iMCD characterized by a catastrophic cytokine storm. Currently, iMCD-TAFRO is regarded as incurable which needs "indefinite" treatment. However, long-term data are sparse, and treatment discontinuation may be possible in a subset of patients. This multicenter, retrospective study analyzed 27 patients who discontinued treatment. All patients had biochemical complete response (CR) at the time of drug discontinuation. Most patients were treated with myeloma-like treatment (59.3%) and only 11.1% received anti-IL-6 therapy. With a median follow-up of 31 months (range, 12-108) after treatment discontinuation, only four patients (14.8%) suffered from progression of disease (PD) and the others (85.2%) maintained biochemical CR. Patients who suffered from PD had a significantly lower pretreatment CRP level than patients maintaining responses (43.7 ± 39.3 vs. 126.4 ± 62.5 mg/L, p = 0.018). No significant impacts of different treatment approaches or duration of treatment on the likelihood of achieving long-term remission were observed. The median time between drug discontinuation to PD (n = 4) was 9.5 months (range, 5-12). These patients all achieved treatment responses again with the same or similar treatment approaches. The estimated PFS at 6 months, 1 year, and 3 years were 96.3%, 85.2%, and 85.2%, respectively. All patients remained alive with a median of 31 months follow-up after drug discontinuation. This study suggests that some iMCD-TAFRO patients might maintain long-term remission after treatment discontinuation. For patients who achieved biochemical CR, an attempt at treatment discontinuation could be considered.
引用
- Zhang L, Ge JY, Li SY, et al. Idiopathic Multicentric Castleman Disease-TAFRO: A Potentially Curable Disease? Am J Hematol. 2026. PMID: 41518092. doi:10.1002/ajh.70199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。